IGC PHARMA, INC. Business Combination, Consideration Transferred
IGC PHARMA, INC. (IGC) had Business Combination, Consideration Transferred of $169.76 thousand as of 2016-02-11, per its 10-K filed 2017-07-14.
Discontinued › Notes › Business Combinations › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Consideration Transferred
us-gaap:BusinessCombinationConsiderationTransferred1 · last filed 2017-07-14
- 2016-02-11: Business Combination, Consideration Transferred $169.76K.
| Period end | Business Combination, Consideration Transferred |
|---|---|
| 2016-02-11 | $169.76K 10-K · filed 2017-07-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |